Icosapent ethyl vs mixed omega-3: reconciling REDUCE-IT and STRENGTH

The two largest cardiovascular outcomes trials of high-dose omega-3 fatty acids reached opposite conclusions within two years of each other. REDUCE-IT showed a 25% relative reduction in major adverse cardiac events with 4 g/day of purified eicosapentaenoic acid (EPA) as the ethyl ester. STRENGTH, testing 4 g/day of a mixed EPA and docosahexaenoic acid (DHA) carboxylic acid formulation against corn oil placebo, was stopped early for futility. The contradiction has not been resolved, and the resulting clinical guidance remains contested.

What the two trials tested

REDUCE-IT randomized 8,179 statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes plus risk factors to icosapent ethyl 4 g/day or mineral-oil placebo. After median 4.9 years, the primary composite cardiovascular endpoint occurred in 17.2% of icosapent versus 22.0% of placebo patients (HR 0.75, p<0.001) [1]. STRENGTH randomized 13,078 similar patients to 4 g/day of a mixed EPA/DHA carboxylic acid (Epanova) or corn-oil placebo. The trial was halted at futility analysis with HR 0.99 for the primary endpoint [2].

Three leading explanations

The first is the active-ingredient hypothesis: pure EPA has cardiovascular benefit that mixed EPA/DHA dilutes or neutralizes. The Japan EPA Lipid Intervention Study (JELIS) showed cardiovascular benefit with 1.8 g/day of pure EPA in a Japanese population [3], partially supporting this view. DHA appears to raise LDL more than EPA in lipidology studies, which could offset benefit. The second is the placebo hypothesis: REDUCE-IT's mineral-oil placebo may have raised inflammatory markers in the control group, exaggerating the apparent benefit of icosapent. CRP rose 32% in the placebo arm of REDUCE-IT, an unusual finding [4]. The third is dosing and pharmacokinetics: on-treatment plasma EPA was substantially higher in REDUCE-IT, suggesting absorption differences between the two formulations.

The placebo controversy specifically

Mineral oil is biologically inert in most respects but may slightly impair statin absorption and may have small inflammatory effects on intestinal lining. The FDA reviewed REDUCE-IT and accepted icosapent ethyl for cardiovascular risk reduction. A subsequent agency review of the placebo controversy concluded that even with adjustment for placebo-attributable effects, a real treatment effect remained, though smaller than the headline 25% [5]. Cardiology guidelines have generally retained the indication while acknowledging the unresolved uncertainty.

What this means for supplement users

Icosapent ethyl is a prescription drug, not a supplement. The 4 g/day dose in REDUCE-IT delivers approximately 4,000 mg of pure EPA — far higher than any over-the-counter fish oil typically provides per day, and concentrated in a single isomer. Most fish oil supplements deliver 180–600 mg of combined EPA and DHA per capsule. Stacking multiple capsules to reach REDUCE-IT-comparable doses with unpurified supplements would (a) deliver substantial DHA, which STRENGTH suggests does not produce the same benefit, and (b) increase atrial fibrillation risk. Patients seeking icosapent's specific cardiovascular benefit need the prescription product.

Why STRENGTH may not have buried the EPA hypothesis

STRENGTH used a different carrier (carboxylic acid versus ethyl ester) and a different EPA-to-DHA ratio. Plasma EPA achieved in STRENGTH was lower than in REDUCE-IT, in part because the patient population was different and the carrier had different absorption kinetics. STRENGTH was not designed as a head-to-head test of pure-EPA versus mixed-omega-3 — its primary comparison was active treatment versus placebo. So the trial does not directly disprove the EPA-specific mechanism; it shows that the specific formulation it tested did not work in its specific population [6].

How clinicians are using this in practice

The 2023 AHA/ACC/multispecialty chronic coronary disease guideline supports icosapent ethyl 4 g/day for high-risk patients with elevated triglycerides on statin therapy [7]. The recommendation comes with the AF caveat and a Class IIa rather than Class I rating because of the placebo controversy. Mixed prescription omega-3 (Lovaza, Omacor) for triglyceride lowering retains FDA approval at 4 g/day but does not carry a cardiovascular outcomes indication. Over-the-counter fish oil supplements have no FDA-recognized cardiovascular indication and should not be presented to patients as substitutes for the prescription products.

The bottom line

REDUCE-IT and STRENGTH disagree, and the most likely explanation is some combination of EPA-specific mechanism, placebo effects, and absorption differences — not a single tidy answer. The current standard of care reflects that complexity: icosapent ethyl 4 g/day is reasonable for high-risk lipid patients despite the placebo controversy, mixed-omega-3 is reasonable for triglyceride lowering but not for outcomes, and over-the-counter supplements remain a low-dose option without outcomes evidence at typical consumer doses.